RPL40B Antibody

What is RPL40B and its function in ribosomal biology?

RPL40B is a component of the 60S ribosomal subunit that plays critical roles in ribosome assembly and function. It's initially synthesized as a ubiquitin fusion protein, with the ubiquitin moiety being efficiently cleaved during processing. The protein has a predicted amino acid sequence of 6.2 kDa but appears larger (approximately 12 kDa) on SDS-PAGE gels due to its highly basic nature affecting migration . Recent research has identified RPL40/eL40 as a target ribosomal protein that can function as a regulatory switch to modulate the production of specific proteins of interest, suggesting it has specialized functions in translation .

How is RPL40B related to ubiquitin fusion proteins?

RPL40B is one of two ribosomal proteins (along with RPS27a) that are produced as ubiquitin fusion proteins. The fusion precursor undergoes efficient processing to yield free RPL40B and ubiquitin. When expressed with tags such as HA, the cleaved RPL40 protein appears at approximately 12 kDa on Western blots. No higher-molecular weight precursor proteins (which would be around 20.6 kDa for RPL40) are typically detected, suggesting that processing of both ribosomal protein-fusion proteins is highly efficient . This unique production method may provide a mechanism for coordinating ribosome biogenesis with ubiquitin production.

What epitopes do RPL40B antibodies typically recognize?

Most commercial RPL40B antibodies target epitopes within the mature ribosomal protein rather than the ubiquitin portion. When working with tagged versions of RPL40B, researchers often use epitope tag antibodies (such as anti-HA or anti-FLAG) to distinguish between the fusion precursor and the mature protein . For studying the ubiquitin-fusion aspects, specialized antibodies that recognize the junction between ubiquitin and RPL40B may be used. Advanced studies may employ antibodies that specifically recognize post-translationally modified forms of RPL40B, similar to those used for detecting ubiquitin modifications .

What is the optimal protocol for Western blot detection of RPL40B?

For optimal Western blot detection of RPL40B:

• Sample preparation:

  • Lyse cells in buffer containing 50 mM Tris-HCl (pH 7.5), 10% glycerol, 1% TritonX-100, 0.1% SDS, 150 mM NaCl, 5 mM EDTA supplemented with protease inhibitors

  • Include 10% β-mercaptoethanol in sample buffer

• Gel electrophoresis:

  • Use 12-14% Bis-Tris PAGE gels for optimal resolution

  • Include low molecular weight markers (5-25 kDa range)

• Transfer and detection:

  • Transfer to 0.2 μm PVDF membrane (optimal for small proteins)

  • Block with Odyssey blocking buffer

  • Incubate with primary antibody (1:1,000-1:10,000 dilution)

  • Use fluorescently-labeled secondary antibodies for quantitative detection

  • Visualize using a digital imaging system such as Odyssey CLx

Note: Due to the basic nature of RPL40B causing aberrant migration (appearing at ~12 kDa rather than the predicted 6.2 kDa), appropriate size controls are essential .

How should I validate RPL40B antibodies before use in critical experiments?

A comprehensive validation strategy for RPL40B antibodies should include:

• Specificity testing:

  • Western blot analysis using lysates from wild-type cells vs. RPL40B knockout/knockdown cells

  • Peptide competition assay using the immunizing peptide

  • Testing cross-reactivity with related ribosomal proteins

• Application-specific validation:

  • For immunoprecipitation: confirm enrichment by Western blot

  • For immunofluorescence: verify expected subcellular localization (nucleolus and cytoplasm)

  • For ChIP: confirm association with expected genomic regions

• Species cross-reactivity:

  • Test reactivity across relevant species (human, mouse, yeast, etc.)

  • Note the high structural conservation between yeast and human eL40 which may enable cross-species applications

• Tag-interference assessment:

  • When using tagged RPL40B, verify that the tag doesn't interfere with antibody binding

  • Compare results with tagged and untagged versions when possible

How can I optimize immunoprecipitation of RPL40B protein complexes?

For effective immunoprecipitation of RPL40B and associated complexes:

• Lysis conditions:

  • For intact ribosomes: Use gentle lysis (e.g., 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM MgCl₂, 1% Triton X-100)

  • Include protease and phosphatase inhibitors

  • For ribosome subunits: Include EDTA to dissociate ribosomes

• Antibody binding:

  • Pre-clear lysate with protein A/G beads

  • Incubate with anti-RPL40B antibody (or anti-tag antibody for tagged versions) for 2-4 hours at 4°C

  • For tagged proteins, direct capture with anti-tag resin can be used

• Washing and elution:

  • Wash 3-5 times with lysis buffer containing reduced detergent

  • For Western blot analysis, elute with SDS sample buffer

  • For maintaining native complexes or mass spectrometry, consider gentler elution methods such as peptide competition

• Controls:

  • Include an isotype control antibody IP

  • If using tagged RPL40B, include untagged controls

  • Consider RNase treatment controls to distinguish RNA-dependent interactions

What controls should I include when using RPL40B antibodies in immunofluorescence studies?

For reliable immunofluorescence with RPL40B antibodies:

• Essential controls:

  • Primary antibody omission control

  • RPL40B knockout/knockdown cells as negative control

  • Pre-absorption with immunizing peptide

  • Isotype control antibody

• Validation controls:

  • Co-staining with nucleolar markers (e.g., fibrillarin)

  • Co-staining with other 60S ribosomal subunit markers

  • Comparison of different fixation methods (paraformaldehyde vs. methanol)

  • Signal confirmation with multiple antibodies against different RPL40B epitopes

• Technical considerations:

  • Optimize antibody concentration (typically 1:50-1:500)

  • Consider antigen retrieval methods if signal is weak

  • Use confocal microscopy for precise subcellular localization

  • Include DAPI or other nuclear counterstain

Expected localization patterns include nucleolar staining (site of ribosome assembly) and cytoplasmic signal (mature ribosomes).

Why does RPL40B appear at a different molecular weight than predicted on SDS-PAGE?

RPL40B consistently migrates at an apparent molecular weight of approximately 12 kDa on SDS-PAGE gels, despite its predicted size of only 6.2 kDa based on amino acid sequence . This discrepancy is attributed to several factors:

• Basic amino acid composition:

  • RPL40B contains numerous basic residues (lysine, arginine)

  • Basic proteins bind less SDS per unit mass than average proteins

  • This results in less negative charge and slower migration than expected

• Abnormal SDS binding:

  • The highly structured nature of ribosomal proteins can affect SDS binding

  • Incomplete denaturation may occur despite reducing conditions

  • Hydrophobic regions may bind disproportionate amounts of SDS

• Post-translational modifications:

  • Modifications like phosphorylation can increase apparent molecular weight

  • Residual amino acids from ubiquitin processing might remain

This migration anomaly is common among ribosomal proteins and should be considered when interpreting Western blot results for RPL40B .

How can I troubleshoot non-specific binding with RPL40B antibodies?

Non-specific binding is a common challenge with ribosomal protein antibodies due to structural similarities among family members. To address this:

• Increase antibody specificity:

  • Use higher dilutions of primary antibody

  • Optimize blocking conditions (try 5% BSA, milk, or commercial blockers)

  • Add 0.1-0.5% Triton X-100 to antibody diluent

  • Pre-absorb antibody with lysate from RPL40B-depleted cells

• Increase washing stringency:

  • Use TBS-T with higher Tween-20 concentration (0.1-0.3%)

  • Include 350-500 mM NaCl in wash buffers

  • Increase number and duration of washes

• Optimize detection conditions:

  • Reduce exposure time or gain settings

  • Use monoclonal antibodies when possible

  • Consider using fluorescent secondary antibodies for better quantification

• Validate specificity:

  • Perform peptide competition assays

  • Include RPL40B knockout/knockdown samples as negative controls

  • Use multiple antibodies against different epitopes

What factors might affect RPL40B antibody sensitivity in experimental applications?

Several factors can influence the sensitivity of RPL40B detection:

• Expression level factors:

  • RPL40B expression can vary by cell type and condition

  • Expression tends to be lower compared to some other ribosomal proteins like RPS27a

  • Cell cycle stage may affect ribosomal protein levels

• Technical factors:

  • Protein extraction method efficiency (stronger lysis may be needed)

  • Transfer efficiency (small proteins may transfer through membrane)

  • Antibody quality and affinity

  • Detection method sensitivity (fluorescent vs. chemiluminescent)

• Sample handling factors:

  • Degradation during sample preparation

  • Protein loss during precipitation steps

  • Incomplete solubilization in sample buffer

  • Interference from other proteins or contaminants

• Improvement strategies:

  • Use 0.2 μm PVDF membrane to prevent protein loss

  • Consider methanol fixation of membrane after transfer

  • Try signal enhancement systems

  • Enrich for ribosomal fractions before analysis

How can I distinguish between free RPL40B and its ubiquitin fusion precursor?

Distinguishing between mature RPL40B and its ubiquitin fusion precursor requires strategic experimental design:

• Size-based discrimination:

  • Cleaved RPL40B appears at approximately 12 kDa

  • The full fusion precursor would appear at approximately 20.6 kDa

  • Use 15-20% gels for optimal resolution in this range

• Dual antibody approach:

  • Use C-terminal targeted antibodies (or C-terminal tags) to detect both forms

  • Use N-terminal antibodies or anti-ubiquitin antibodies to detect only the precursor

  • In tagged constructs, use antibodies against different tags as described in :

    • Anti-HA (C-terminal tag) detected cleaved RPL40

    • Anti-FLAG (N-terminal ubiquitin tag) detected only the precursor or free ubiquitin

• Validated controls:

  • Purified recombinant RPL40B as size reference

  • Proteasome inhibitors may increase detection of precursor forms

  • Mutation of the cleavage site to prevent processing

Research suggests that processing of RPL40B fusion protein is highly efficient under normal conditions, with little detectable precursor .

How can RPL40B antibodies be used to study specialized ribosomes?

RPL40B antibodies can be instrumental in investigating the emerging field of specialized ribosomes:

• Compositional heterogeneity analysis:

  • Use RPL40B antibodies in co-immunoprecipitation to isolate specific ribosome populations

  • Analyze associated proteins and RNAs using mass spectrometry and RNA-seq

  • Compare RPL40B incorporation across different tissues and conditions

  • Study how RPL40B variants affect ribosome composition

• Translational specificity studies:

  • Immunoprecipitate RPL40B-containing ribosomes and analyze associated mRNAs

  • Use ribosome profiling with RPL40B immunoprecipitation to identify specifically translated mRNAs

  • Examine translational efficiency of different mRNAs in the presence or absence of RPL40B

• Structure-function relationships:

  • Use RPL40B antibodies for structural analysis of ribosomes in different functional states

  • Map RPL40B position in specialized ribosomes using cryo-EM approaches

  • Study conformational changes upon small molecule binding to RPL40B

The RiboScreen™ technology described in represents an application of this concept, employing ribosomal variant strains to identify ribosomal proteins like RPL40/eL40 that can act as switches to regulate specific protein production.

What methodologies can be used to investigate RPL40B's role in translation regulation?

To study RPL40B's regulatory functions in translation, as suggested by its identification as a translation regulatory switch in RiboScreen™ technology :

• Polysome profiling with RPL40B detection:

  • Fractionate polysomes on sucrose gradients

  • Detect RPL40B distribution across fractions by Western blot

  • Compare profiles under different conditions (stress, differentiation, etc.)

  • Analyze mRNAs in RPL40B-enriched fractions by RT-PCR or sequencing

• Ribosome footprinting approaches:

  • Immunoprecipitate RPL40B-containing ribosomes

  • Sequence protected mRNA fragments

  • Compare with total ribosome footprinting data

  • Identify mRNAs preferentially translated by RPL40B-containing ribosomes

• Reporter-based systems:

  • Use dual luciferase assays as described in

  • Test specific mRNA elements for RPL40B-dependent translation

  • Examine the effect of RPL40B depletion or mutation on reporter expression

  • Study the impact of RPL40B-binding small molecules on translation efficiency

• In vitro translation systems:

  • Reconstitute translation systems with or without RPL40B

  • Test the translation of specific mRNAs

  • Examine the effect of RPL40B-binding molecules on translation

How can RPL40B antibodies facilitate research on the RiboScreen™ technology platform?

Based on search result , RPL40B/eL40 has been identified as a key component in RiboScreen™ technology, and antibodies can support this research in several ways:

• Validation of target engagement:

  • Confirm binding of small molecules to RPL40B using competitive binding assays with antibodies

  • Perform cellular thermal shift assays (CETSA) with RPL40B antibodies to verify target engagement

  • Use antibodies to track changes in RPL40B localization or interactions upon compound treatment

• Mechanism studies:

  • Immunoprecipitate RPL40B to identify changes in binding partners upon small molecule treatment

  • Monitor RPL40B incorporation into ribosomes in the presence of compounds

  • Track post-translational modifications that may be affected by small molecule binding

• Translation output analysis:

  • Correlate changes in target protein production (e.g., tropoelastin) with RPL40B status

  • Use Western blotting to quantify protein expression changes in response to RPL40B-targeting compounds

  • Monitor dual luciferase reporter activity in parallel with RPL40B levels to establish causality

The research described in demonstrated that small molecules binding to eL40 could boost tropoelastin production up to two-fold in a dose-dependent manner, highlighting the potential of this approach for protein-level therapeutic interventions.

What techniques can be used to study the unique aspects of RPL40B as a ubiquitin fusion protein?

The unique nature of RPL40B as a ubiquitin fusion protein offers opportunities to study the intersection of the ubiquitin system and ribosome biology:

• Processing analysis:

  • Use pulse-chase experiments with RPL40B antibodies to track processing kinetics

  • Identify the proteases involved using inhibitors and genetic approaches

  • Create fusion protein variants with mutations at the cleavage site

  • Investigate regulation of processing under different cellular conditions

• Ubiquitin-ribosome crosstalk studies:

  • Use mass spectrometry to identify post-translational modifications on both portions

  • Study whether free ubiquitin levels affect RPL40B processing and function

  • Investigate potential non-canonical functions of the ubiquitin moiety before cleavage

• Specialized methodology:

  • Employ GlyGly-remnant antibodies to study the processed junction

  • Use HA-FLAG dual tagging systems as described in

  • Apply SILAC or TMT labeling for quantitative proteomics

  • Develop specific antibodies against the ubiquitin-RPL40B junction

• Ribosome quality control connections:

  • Investigate RPL40B in ribosome-associated degradation

  • Study whether ubiquitin fusion affects ribosome assembly efficiency

  • Examine potential roles in stress responses and proteostasis

These approaches can provide insights into the evolutionary significance of producing ribosomal proteins as ubiquitin fusions and potential regulatory mechanisms at the intersection of ribosome biogenesis and ubiquitin homeostasis.